USANA Health Sciences (NYSE:USNA) Issues Earnings Results

USANA Health Sciences (NYSE:USNA) posted its quarterly earnings data on Tuesday. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07, Yahoo Finance reports. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. The company had revenue of $200.22 million during the quarter, compared to analysts’ expectations of $208.45 million. During the same period in the prior year, the business posted $0.59 earnings per share. USANA Health Sciences updated its FY 2024 guidance to 2.450-2.450 EPS.

USANA Health Sciences Trading Up 3.4 %

Shares of USNA opened at $37.81 on Friday. USANA Health Sciences has a 12-month low of $34.15 and a 12-month high of $54.81. The firm has a 50-day moving average price of $37.96 and a 200 day moving average price of $42.51. The firm has a market capitalization of $720.28 million, a P/E ratio of 13.36, a P/E/G ratio of 1.15 and a beta of 0.89.

Insider Activity at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 674 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total value of $26,751.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Gilbert A. Fuller sold 674 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total value of $26,751.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Paul A. Jones sold 6,266 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 7,940 shares of company stock valued at $311,670. 0.33% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on USNA. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th. DA Davidson dropped their target price on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a report on Wednesday.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.